Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old drug, new hope? ivermectin tackles stubborn skin disease

NCT ID NCT07286604

Disease control Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested whether the drug ivermectin could safely treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can appear after recovery from visceral leishmaniasis. Ten otherwise healthy adults with PKDL took ivermectin pills for five days each month for three months. Researchers monitored for side effects and checked if skin lesions improved. The goal was to see if ivermectin could offer a simpler, shorter treatment option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

10 people

The number who actually took part.

Started

Mar 2022

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed PKDL case of either sex aged more than 5 years, * Clinically healthy except skin lesions, * Free from chronic illness * Normal serum glucose, creatinine and SGPT, Hb ≥ 10 g/dL (male) and 8 g/dL (Female) * Voluntary participation through informed voluntary written consent. Exclusion Criteria: * Incompliance with any inclusion criteria * Patients who received VL or PKDL treatment within 12 months * Pregnant / lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post kala-azar dermal leishmaniasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

visceral leishmaniasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post kala-azar dermal leishmaniasis

Contacts and locations

Locations

  • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

    Dhaka, 1212, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.